Dual Kaletra/Isentress HIV regimen looks as effective as traditional HAART
This article was originally published in Scrip
Executive Summary
A two-drug HIV treatment regimen consisting of Abbott's protease inhibitor Kaletra (lopinavir 400mg/ritonavir 100mg) and Merck & Co's integrase inhibitor Isentress (raltegravir) has comparable efficacy to a traditional three-drug highly active antiretroviral treatment (HAART) regimen of Kaletra and Gilead Sciences' combined nucleotide/nucleoside reverse transcriptase inhibitor Truvada (emtricitabine 300mg and tenofovir disoproxil fumarate 200mg), preliminary study findings suggest.